Loading...
XNAS
LRMR
Market cap285mUSD
Oct 08, Last price  
2.70USD
1D
-1.82%
1Q
-36.92%
Jan 2017
-92.92%
IPO
-98.86%
Name

Larimar Therapeutics Inc

Chart & performance

D1W1MN
XNAS:LRMR chart
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
43.75%
Rev. gr., 5y
%
Revenues
0
Net income
-166m
L+105.54%
-13,157,000-13,880,000-14,027,000-36,570,000-74,286,000-57,878,000-52,028,000-61,368,000-23,132,000-42,327,000-50,636,000-35,355,000-36,949,000-80,604,000-165,673,000
CFO
-113m
L+59.98%
-12,274,000-13,589,000-15,004,000-28,241,000-59,554,000-51,975,000-43,784,000-51,487,000-22,699,000-42,199,000-42,105,000-27,569,000-33,459,000-70,760,000-113,201,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.

Key people

Peter Barrett
Independent Chairman of the Board · since 2014
Brian P. McVeigh
Chief Business Officer · since 2018
Priya Singhal
Head of Research and Development · since 2019
Thomas O. Daniel
Independent Director · since 2016
Wendy Everett
Independent Director · since 2018
John Lamattina
Independent Director
URL
https://larimartx.com/
IPO date
Jun 19, 2014
Employees
26
Domiciled in
US
Incorporated in
US
Legal address
c/o THE CORPORATION TRUST COMPANY, CORPORATION TRUST CENTER 1209 ORANGE ST
WILMINGTON, DE 19808
US
Headquarters
175 Portland Street, 4th Floor
Boston, MA 02114
US
Previous name
ZAFGEN, INC.

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT